Biosimilar Insulin-China Market Status and Trend Report 2013-2023
Report Summary
Biosimilar Insulin-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole China and Regional Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023
Main market players of Biosimilar Insulin in China, with company and product introduction, position in the Biosimilar Insulin market
Market status and development trend of Biosimilar Insulin by types and applications
Cost and profit status of Biosimilar Insulin, and marketing status
Market growth drivers and challenges
The report segments the China Biosimilar Insulin market as:
China Biosimilar Insulin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North China
Northeast China
East China
Central & South China
Southwest China
Northwest China
China Biosimilar Insulin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins
China Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Medical Center
China Biosimilar Insulin Market: Players Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biosimilar Insulin-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole China and Regional Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023
Main market players of Biosimilar Insulin in China, with company and product introduction, position in the Biosimilar Insulin market
Market status and development trend of Biosimilar Insulin by types and applications
Cost and profit status of Biosimilar Insulin, and marketing status
Market growth drivers and challenges
The report segments the China Biosimilar Insulin market as:
China Biosimilar Insulin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North China
Northeast China
East China
Central & South China
Southwest China
Northwest China
China Biosimilar Insulin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins
China Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Medical Center
China Biosimilar Insulin Market: Players Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOSIMILAR INSULIN
1.1 Definition of Biosimilar Insulin in This Report
1.2 Commercial Types of Biosimilar Insulin
1.2.1 Rapid Acting Insulins
1.2.2 Short Acting Insulins
1.2.3 Intermediate Insulins
1.2.4 Long Lasting Insulins
1.3 Downstream Application of Biosimilar Insulin
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Medical Center
1.4 Development History of Biosimilar Insulin
1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
1.5.1 China Biosimilar Insulin Market Status and Trend 2013-2023
1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biosimilar Insulin in China 2013-2017
2.2 Consumption Market of Biosimilar Insulin in China by Regions
2.2.1 Consumption Volume of Biosimilar Insulin in China by Regions
2.2.2 Revenue of Biosimilar Insulin in China by Regions
2.3 Market Analysis of Biosimilar Insulin in China by Regions
2.3.1 Market Analysis of Biosimilar Insulin in North China 2013-2017
2.3.2 Market Analysis of Biosimilar Insulin in Northeast China 2013-2017
2.3.3 Market Analysis of Biosimilar Insulin in East China 2013-2017
2.3.4 Market Analysis of Biosimilar Insulin in Central & South China 2013-2017
2.3.5 Market Analysis of Biosimilar Insulin in Southwest China 2013-2017
2.3.6 Market Analysis of Biosimilar Insulin in Northwest China 2013-2017
2.4 Market Development Forecast of Biosimilar Insulin in China 2018-2023
2.4.1 Market Development Forecast of Biosimilar Insulin in China 2018-2023
2.4.2 Market Development Forecast of Biosimilar Insulin by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Biosimilar Insulin in China by Types
3.1.2 Revenue of Biosimilar Insulin in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Biosimilar Insulin in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biosimilar Insulin in China by Downstream Industry
4.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biosimilar Insulin by Downstream Industry in North China
4.2.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Northeast China
4.2.3 Demand Volume of Biosimilar Insulin by Downstream Industry in East China
4.2.4 Demand Volume of Biosimilar Insulin by Downstream Industry in Central & South China
4.2.5 Demand Volume of Biosimilar Insulin by Downstream Industry in Southwest China
4.2.6 Demand Volume of Biosimilar Insulin by Downstream Industry in Northwest China
4.3 Market Forecast of Biosimilar Insulin in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN
5.1 China Economy Situation and Trend Overview
5.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Biosimilar Insulin in China by Major Players
6.2 Revenue of Biosimilar Insulin in China by Major Players
6.3 Basic Information of Biosimilar Insulin by Major Players
6.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Players
6.3.2 Employees and Revenue Level of Biosimilar Insulin Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Biosimilar Insulin Product
7.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Biogenomics
7.2.1 Company profile
7.2.2 Representative Biosimilar Insulin Product
7.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
7.3 Eli Lilly
7.3.1 Company profile
7.3.2 Representative Biosimilar Insulin Product
7.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 Gan&Lee Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative Biosimilar Insulin Product
7.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
7.5 Geropharm
7.5.1 Company profile
7.5.2 Representative Biosimilar Insulin Product
7.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
7.6 Julphar Gulf Pharmaceutical Industries
7.6.1 Company profile
7.6.2 Representative Biosimilar Insulin Product
7.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
7.7 Paras Biopharmaceuticals
7.7.1 Company profile
7.7.2 Representative Biosimilar Insulin Product
7.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
7.8 Samsung Bioepis
7.8.1 Company profile
7.8.2 Representative Biosimilar Insulin Product
7.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
7.9 Sedico
7.9.1 Company profile
7.9.2 Representative Biosimilar Insulin Product
7.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
7.10 Wockhardt
7.10.1 Company profile
7.10.2 Representative Biosimilar Insulin Product
7.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
7.11 Teva Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Biosimilar Insulin Product
7.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN
8.1 Industry Chain of Biosimilar Insulin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN
9.1 Cost Structure Analysis of Biosimilar Insulin
9.2 Raw Materials Cost Analysis of Biosimilar Insulin
9.3 Labor Cost Analysis of Biosimilar Insulin
9.4 Manufacturing Expenses Analysis of Biosimilar Insulin
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILAR INSULIN
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Biosimilar Insulin in This Report
1.2 Commercial Types of Biosimilar Insulin
1.2.1 Rapid Acting Insulins
1.2.2 Short Acting Insulins
1.2.3 Intermediate Insulins
1.2.4 Long Lasting Insulins
1.3 Downstream Application of Biosimilar Insulin
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Medical Center
1.4 Development History of Biosimilar Insulin
1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
1.5.1 China Biosimilar Insulin Market Status and Trend 2013-2023
1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biosimilar Insulin in China 2013-2017
2.2 Consumption Market of Biosimilar Insulin in China by Regions
2.2.1 Consumption Volume of Biosimilar Insulin in China by Regions
2.2.2 Revenue of Biosimilar Insulin in China by Regions
2.3 Market Analysis of Biosimilar Insulin in China by Regions
2.3.1 Market Analysis of Biosimilar Insulin in North China 2013-2017
2.3.2 Market Analysis of Biosimilar Insulin in Northeast China 2013-2017
2.3.3 Market Analysis of Biosimilar Insulin in East China 2013-2017
2.3.4 Market Analysis of Biosimilar Insulin in Central & South China 2013-2017
2.3.5 Market Analysis of Biosimilar Insulin in Southwest China 2013-2017
2.3.6 Market Analysis of Biosimilar Insulin in Northwest China 2013-2017
2.4 Market Development Forecast of Biosimilar Insulin in China 2018-2023
2.4.1 Market Development Forecast of Biosimilar Insulin in China 2018-2023
2.4.2 Market Development Forecast of Biosimilar Insulin by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Biosimilar Insulin in China by Types
3.1.2 Revenue of Biosimilar Insulin in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Biosimilar Insulin in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biosimilar Insulin in China by Downstream Industry
4.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biosimilar Insulin by Downstream Industry in North China
4.2.2 Demand Volume of Biosimilar Insulin by Downstream Industry in Northeast China
4.2.3 Demand Volume of Biosimilar Insulin by Downstream Industry in East China
4.2.4 Demand Volume of Biosimilar Insulin by Downstream Industry in Central & South China
4.2.5 Demand Volume of Biosimilar Insulin by Downstream Industry in Southwest China
4.2.6 Demand Volume of Biosimilar Insulin by Downstream Industry in Northwest China
4.3 Market Forecast of Biosimilar Insulin in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN
5.1 China Economy Situation and Trend Overview
5.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Biosimilar Insulin in China by Major Players
6.2 Revenue of Biosimilar Insulin in China by Major Players
6.3 Basic Information of Biosimilar Insulin by Major Players
6.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Players
6.3.2 Employees and Revenue Level of Biosimilar Insulin Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Biosimilar Insulin Product
7.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Biogenomics
7.2.1 Company profile
7.2.2 Representative Biosimilar Insulin Product
7.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
7.3 Eli Lilly
7.3.1 Company profile
7.3.2 Representative Biosimilar Insulin Product
7.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
7.4 Gan&Lee Pharmaceuticals
7.4.1 Company profile
7.4.2 Representative Biosimilar Insulin Product
7.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
7.5 Geropharm
7.5.1 Company profile
7.5.2 Representative Biosimilar Insulin Product
7.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
7.6 Julphar Gulf Pharmaceutical Industries
7.6.1 Company profile
7.6.2 Representative Biosimilar Insulin Product
7.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
7.7 Paras Biopharmaceuticals
7.7.1 Company profile
7.7.2 Representative Biosimilar Insulin Product
7.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
7.8 Samsung Bioepis
7.8.1 Company profile
7.8.2 Representative Biosimilar Insulin Product
7.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
7.9 Sedico
7.9.1 Company profile
7.9.2 Representative Biosimilar Insulin Product
7.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
7.10 Wockhardt
7.10.1 Company profile
7.10.2 Representative Biosimilar Insulin Product
7.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
7.11 Teva Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Biosimilar Insulin Product
7.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN
8.1 Industry Chain of Biosimilar Insulin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN
9.1 Cost Structure Analysis of Biosimilar Insulin
9.2 Raw Materials Cost Analysis of Biosimilar Insulin
9.3 Labor Cost Analysis of Biosimilar Insulin
9.4 Manufacturing Expenses Analysis of Biosimilar Insulin
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILAR INSULIN
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
